DMTRF Stock Chart & Stats
$2.50
$0.00(0.00%)
At close: 4:00 PM EDT
$2.50
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.50 - $3.96
Previous CloseN/A
Volume200.00
Average Volume (3M)0.00
Market Cap
$301.46M
Enterprise Value$63.80K
Total Cash (Recent Filing)$2.83B
Total Debt (Recent Filing)$600.00M
Price to Earnings (P/E)10.3
Beta<0.01
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)34.88
Shares Outstanding127,981,480
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)9.04
Price to Sales (P/S)5.65
P/FCF Ratio166.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained, accelerating revenue growth indicates expanding product adoption and market penetration in medical devices. Over 2-6 months this supports higher operating leverage, improved pricing power, and a larger addressable base for cross-selling and scaling fixed-cost absorption.
Balance Sheet HealthMaterial deleveraging and a stronger equity base reduce refinancing risk and free capacity to invest in R&D or commercial expansion. A healthier capital structure provides durable financial flexibility and resilience against episodic demand shocks.
Profitability TurnaroundA clear switch to operating profit and net income reflects improved unit economics or better cost control. If sustained, this creates a foundation for retained earnings, internal funding of growth initiatives, and reduces reliance on external capital over the medium term.
Bears Say
Weak Cash ConversionLow conversion of reported profits into cash suggests earnings quality issues, working-capital pressure, or one-time accounting effects. Over months this limits ability to self-fund growth, raises liquidity risk, and makes the company vulnerable if profitability weakens.
Margin Consistency RiskVolatile historical margins imply that profitability may be sensitive to pricing, input costs, or product mix. Without consistent margin improvement, operating profits could reverse, undermining long-term cash generation and the credibility of the turnaround.
Legacy Leverage & Funding RiskPast high leverage and thin equity highlight a legacy of funding strain. If the company cannot consistently convert earnings to cash, residual refinancing risk and constrained strategic optionality could re-emerge over the medium term.
DMTRF FAQ
What was 3-D Matrix Ltd’s price range in the past 12 months?
3-D Matrix Ltd lowest stock price was $1.50 and its highest was $3.96 in the past 12 months.
What is 3-D Matrix Ltd’s market cap?
3-D Matrix Ltd’s market cap is $301.46M.
When is 3-D Matrix Ltd’s upcoming earnings report date?
3-D Matrix Ltd’s upcoming earnings report date is Sep 10, 2026 which is in 2 days.
How were 3-D Matrix Ltd’s earnings last quarter?
3-D Matrix Ltd released its earnings results on Jun 11, 2026. The company reported $0.096 earnings per share for the quarter.
Is 3-D Matrix Ltd overvalued?
According to Wall Street analysts 3-D Matrix Ltd’s price is currently Overvalued.
Does 3-D Matrix Ltd pay dividends?
3-D Matrix Ltd does not currently pay dividends.
What is 3-D Matrix Ltd’s EPS estimate?
3-D Matrix Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 3-D Matrix Ltd have?
3-D Matrix Ltd has 127,981,480 shares outstanding.
What happened to 3-D Matrix Ltd’s price movement after its last earnings report?
3-D Matrix Ltd reported an EPS of $0.096 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of 3-D Matrix Ltd?
Currently, no hedge funds are holding shares in DMTRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
3-D Matrix Ltd
3-D Matrix, Ltd. specializes in pioneering self-assembling peptide technology. Its flagship product, PuraMatrix, is an innovative self-assembling peptide hydrogel with diverse applications across medical fields, including regenerative medicine, cell therapy, advanced drug delivery systems, and surgical interventions. This Tokyo-based firm was established in 2004.
Technical Analysis
PHC Holdings Corp.
―
Eiken Chemical Co., Ltd.
―
Techno Medica Co., Ltd.
―
Nihon Kohden Corporation
―
Koken Ltd.
―
Ownership Overview
―
Insiders
0.03% Other Institutional Investors
99.93% Public Companies and
Individual Investors